A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study

Jadoon, Khalid; Tan, Garry D; O’Sullivan, Saoirse E.

doi:10.1172/jci.insight.93760

Cited by 92 publications

(81 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We used CBD at 10 mg/kg for 14 days since its chronic i.p administration had a beneficial effect on cardiovascular tissues (including decreases in oxidative stress) from diabetic (7 days; [50]) and septic rats (9 days; [28]) and from mice with diabetic (11 weeks; [22]) and doxorubicin-induced cardiomyopathy (5 days; [26]) and experimental autoimmune myocarditis (46 days; [51]). Note that CBD was used at~10 mg/kg also in several acute experiments [10,13,15].…”

Section: Generalmentioning

confidence: 99%

“…CBD may become a strategy also for the treatment of cardiovascular diseases, including hypertension [3,9]. To date, blood pressure-lowering effects of CBD were observed under stress conditions in humans [10][11][12] and in stressed animals [13,14]. However, the effect of CBD on the blood pressure of hypertensive individuals has been studied in one study only; in a paper on conscious spontaneously hypertensive rats [15], a single intraperitoneal dose of CBD (10 mg/kg) failed to affect blood pressure.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism

Remiszewski

Jarocka-Karpowicz

Biernacki

et al. 2020

IJMS

View full text Add to dashboard Cite

We investigated the influence of cannabidiol (CBD) on blood pressure (BP) and heart rate (HR) in spontaneously (SHR) and deoxycorticosterone (DOCA-salt) hypertensive rats. Hypertension was connected with increases in cardiac and plasma markers of lipid peroxidation in both models, whereas cardiac endocannabinoid levels decreased in SHR and increased in DOCA-salt. CBD (10 mg/kg once a day for 2 weeks) did not modify BP and HR in hypertension but counteracted pro-oxidant effects. Moreover, it decreased cardiac or plasma levels of anandamide, 2-arachidonoylglycerol and oleoyl ethanolamide in DOCA-salt and inhibited the activity of fatty acid amide hydrolase (FAAH) in both models. In the respective normotensive control rats, CBD increased lipid peroxidation, free fatty acid levels and FAAH activity. In conclusion, chronic CBD administration does not possess antihypertensive activity in a model of primary and secondary (DOCA-salt) hypertension, despite its antioxidant effect. The latter may be direct rather than based on the endocannabinoid system. The unexpected CBD-related increase in lipid peroxidation in normotensive controls may lead to untoward effects; thus, caution should be kept if CBD is used therapeutically.

show abstract

Section: Generalmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism

Remiszewski

Jarocka-Karpowicz

Biernacki

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…The dose of CBD was chosen based on our recent study. 19 The trial All measures, visits and analyses were performed blinded to treatment allocation. Randomisation was performed using computerised random number generation.…”

Section: Methodsmentioning

confidence: 99%

“…To help address this, we recently showed that a single dose of CBD (600 mg) causes a reduction in blood pressure at rest and in response to stress in healthy males. 19 The aim of this study was to establish if we could replicate the findings and examine whether the response was affected by repeated dosing with CBD.…”

mentioning

confidence: 99%

The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial

Sultan

O’Sullivan

England

2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

Background:In vivo studies show that cannabidiol (CBD) acutely reduces blood pressure (BP) in men. The aim of this study was to assess the effects of repeated CBD dosing on haemodynamics.Methods: Twenty-six healthy males were given CBD (600 mg) or placebo orally for seven days in a randomised, placebo-controlled, double-blind, parallel study (n = 13/ group). Cardiovascular parameters were assessed at rest and in response to isometric exercise after acute and repeated dosing using Finometer ® , Vicorder ® and Duplex ultrasound.Results: Compared to placebo, CBD significantly reduced resting mean arterial pressure (P = .04, two-way ANOVA, mean difference (MD) -2 mmHg, 95% CI -3.6 to −0.3) after acute dosing, but not after repeated dosing. In response to stress, volunteers who had taken CBD had lower systolic BP after acute (P = .001, two-way ANOVA, MD −6 mmHg, 95% CI -10 to −1) and repeated (P = .02, two-way ANOVA, MD −5.7 mmHg, 95% CI -10 to −1) dosing. Seven days of CBD increased internal carotid artery diameter (MD +0.55 mm, P = .01). Within the CBD group, repeated dosing reduced arterial stiffness by day 7 (pulse wave velocity; MD −0.44 m/s, P = .05) and improved endothelial function (flow mediation dilatation, MD +3.5%, P = .02, n = 6 per group), compared to day 1.Conclusion: CBD reduces BP at rest after a single dose but the effect is lost after seven days of treatment (tolerance); however, BP reduction during stress persists.The reduction in arterial stiffness and improvements in endothelial function after repeated CBD dosing are findings that warrant further investigation in populations with vascular diseases. K E Y W O R D S blood flow, blood pressure, cannabidiol, cardiovascular system, haemodynamics Saoirse E. O'Sullivan and Timothy J. England joint last authorsThe authors confirm that the Principal Investigator for this paper is Timothy J. England and that he had direct clinical responsibility for participants.

show abstract

“…The epidemiological estimates from the US National Health and Nutrition Examination Survey (NHANES; 2005–2012; n = 12 426) showed that, compared with “never use”, “recent” cannabis use (at least once in the 30 days prior to the interview) was associated with higher systolic but not diastolic BP in an age‐adjusted and sex‐adjusted model (Alshaarawy and Elbaz, ). When administered alone, the non‐psychoactive phytocannabinoid CBD decreased resting BP and the stress‐induced increase in BP (Jadoon et al ., ). In contrast to acute administration, chronic use of cannabis may elicit a long‐lasting bradycardia and prolonged reduction in BP (see Malinowska et al ., ).…”

Section: Cannabinoids In Human Arterial Hypertensionmentioning

confidence: 97%

Cannabinoids in arterial, pulmonary and portal hypertension – mechanisms of action and potential therapeutic significance

Malinowska

Toczek

Pędzińska-Betiuk

et al. 2018

British J Pharmacology

View full text Add to dashboard Cite

The endocannabinoid system is overactivated in arterial, pulmonary and portal hypertension. In this paper, we present limited clinical data concerning the role of cannabinoids in human hypertension including polymorphism of endocannabinoid system components. We underline differences between the acute cannabinoid administration and their potential hypotensive effect after chronic application in experimental hypertension. We discuss pleiotropic effects of cannabinoids on the cardiovascular system mediated via numerous neuronal and non‐neuronal mechanisms both in normotension and in hypertension. The final results are dependent on the model of hypertension, age, sex, the cannabinoid ligands used or the action via endocannabinoid metabolites. More experimental and clinical studies are needed to clarify the role of endocannabinoids in hypertension, not only in the search for new therapeutic strategies but also in the context of cardiovascular effects of cannabinoids and the steadily increasing legalization of cannabis use for recreational and medical purposes. Linked Articles This article is part of a themed section on 8 th European Workshop on Cannabinoid Research. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc

show abstract

A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study

Cited by 92 publications

References 41 publications

Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism

Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism

The effects of acute and sustained cannabidiol dosing for seven days on the haemodynamics in healthy men: A randomised controlled trial

Cannabinoids in arterial, pulmonary and portal hypertension – mechanisms of action and potential therapeutic significance

Contact Info

Product

Resources

About